Clinical Trials Directory

Trials / Sponsors / Hangzhou Sumgen Biotech Co., Ltd.

Hangzhou Sumgen Biotech Co., Ltd.

Industry · 9 registered clinical trials — 4 currently recruiting.

StatusTrialPhaseStarted
RecruitingTo Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
Phase 22026-03-26
Not Yet RecruitingTo Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Phase 1 / Phase 22026-03-14
RecruitingA Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexameth
Relapsed/Refractory Multiple Myeloma
Phase 32024-06-14
Active Not RecruitingSG2918 For Advanced Malignant Tumors
Advanced Malignant Tumors
Phase 12023-12-26
Active Not RecruitingSG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
Phase 12023-11-10
Active Not RecruitingAn Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
Advanced Solid Tumors
Phase 12023-09-27
RecruitingSG1906 for CLDN18.2-Positive Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors
Phase 12023-05-30
TerminatedSG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
Hematological Malignancy, Lymphoma
Phase 12023-03-03
Active Not RecruitingSG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignanci
Relapsed or Refractory Multiple Myeloma, Hematological Malignancy
Phase 12021-11-04